|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DIS3L2 |
Gene summary for DIS3L2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DIS3L2 | Gene ID | 129563 |
| Gene name | DIS3 like 3'-5' exoribonuclease 2 | |
| Gene Alias | FAM6A | |
| Cytomap | 2q37.1 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q8IYB7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 129563 | DIS3L2 | P32T-E | Human | Esophagus | ESCC | 4.83e-15 | 2.29e-01 | 0.1666 |
| 129563 | DIS3L2 | P36T-E | Human | Esophagus | ESCC | 7.61e-10 | 2.27e-01 | 0.1187 |
| 129563 | DIS3L2 | P37T-E | Human | Esophagus | ESCC | 5.60e-11 | 2.51e-01 | 0.1371 |
| 129563 | DIS3L2 | P39T-E | Human | Esophagus | ESCC | 1.18e-02 | 8.62e-02 | 0.0894 |
| 129563 | DIS3L2 | P40T-E | Human | Esophagus | ESCC | 2.73e-04 | 1.15e-01 | 0.109 |
| 129563 | DIS3L2 | P42T-E | Human | Esophagus | ESCC | 5.38e-14 | 2.03e-01 | 0.1175 |
| 129563 | DIS3L2 | P44T-E | Human | Esophagus | ESCC | 6.03e-08 | 1.43e-01 | 0.1096 |
| 129563 | DIS3L2 | P47T-E | Human | Esophagus | ESCC | 7.76e-15 | 1.58e-01 | 0.1067 |
| 129563 | DIS3L2 | P48T-E | Human | Esophagus | ESCC | 5.05e-22 | 3.25e-01 | 0.0959 |
| 129563 | DIS3L2 | P49T-E | Human | Esophagus | ESCC | 2.06e-07 | 4.98e-01 | 0.1768 |
| 129563 | DIS3L2 | P52T-E | Human | Esophagus | ESCC | 1.45e-15 | 2.77e-01 | 0.1555 |
| 129563 | DIS3L2 | P54T-E | Human | Esophagus | ESCC | 9.68e-12 | 3.06e-01 | 0.0975 |
| 129563 | DIS3L2 | P56T-E | Human | Esophagus | ESCC | 3.04e-08 | 6.58e-01 | 0.1613 |
| 129563 | DIS3L2 | P57T-E | Human | Esophagus | ESCC | 1.17e-16 | 2.41e-01 | 0.0926 |
| 129563 | DIS3L2 | P61T-E | Human | Esophagus | ESCC | 3.08e-17 | 3.49e-01 | 0.099 |
| 129563 | DIS3L2 | P62T-E | Human | Esophagus | ESCC | 9.48e-50 | 8.20e-01 | 0.1302 |
| 129563 | DIS3L2 | P65T-E | Human | Esophagus | ESCC | 9.43e-15 | 1.61e-01 | 0.0978 |
| 129563 | DIS3L2 | P74T-E | Human | Esophagus | ESCC | 1.17e-13 | 2.93e-01 | 0.1479 |
| 129563 | DIS3L2 | P75T-E | Human | Esophagus | ESCC | 3.79e-18 | 3.29e-01 | 0.1125 |
| 129563 | DIS3L2 | P76T-E | Human | Esophagus | ESCC | 7.64e-17 | 2.15e-01 | 0.1207 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:1903313 | Colorectum | AD | positive regulation of mRNA metabolic process | 44/3918 | 118/18723 | 3.20e-05 | 5.87e-04 | 44 |
| GO:0000956 | Colorectum | AD | nuclear-transcribed mRNA catabolic process | 40/3918 | 112/18723 | 2.11e-04 | 2.79e-03 | 40 |
| GO:0061014 | Colorectum | AD | positive regulation of mRNA catabolic process | 32/3918 | 87/18723 | 4.81e-04 | 5.27e-03 | 32 |
| GO:0061157 | Colorectum | AD | mRNA destabilization | 30/3918 | 84/18723 | 1.24e-03 | 1.09e-02 | 30 |
| GO:0050779 | Colorectum | AD | RNA destabilization | 30/3918 | 88/18723 | 2.83e-03 | 2.12e-02 | 30 |
| GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DIS3L2 | SNV | Missense_Mutation | rs376340398 | c.1459N>T | p.Arg487Cys | p.R487C | Q8IYB7 | protein_coding | tolerated(0.14) | benign(0.224) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.478N>A | p.Asp160Asn | p.D160N | Q8IYB7 | protein_coding | tolerated(0.4) | benign(0.071) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.665N>C | p.Arg222Thr | p.R222T | Q8IYB7 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.2366A>G | p.Tyr789Cys | p.Y789C | Q8IYB7 | protein_coding | deleterious(0) | benign(0.073) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DIS3L2 | SNV | Missense_Mutation | rs770702636 | c.1693N>A | p.Gly565Arg | p.G565R | Q8IYB7 | protein_coding | deleterious(0.01) | benign(0.427) | TCGA-D8-A27N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol+adriamycin+cyclophosphamide+herceptin | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.983A>G | p.Glu328Gly | p.E328G | Q8IYB7 | protein_coding | deleterious(0) | possibly_damaging(0.696) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.2376N>C | p.Gln792His | p.Q792H | Q8IYB7 | protein_coding | deleterious(0.03) | benign(0) | TCGA-C5-A7X8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| DIS3L2 | SNV | Missense_Mutation | novel | c.1417G>A | p.Glu473Lys | p.E473K | Q8IYB7 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DIS3L2 | SNV | Missense_Mutation | novel | c.821G>A | p.Arg274Gln | p.R274Q | Q8IYB7 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DIS3L2 | SNV | Missense_Mutation | rs368280072 | c.2381N>A | p.Arg794His | p.R794H | Q8IYB7 | protein_coding | deleterious(0) | benign(0.356) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |